<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: In individuals without <z:e sem="disease" ids="C0240066" disease_type="Disease or Syndrome" abbrv="">iron deficiency</z:e>, the soluble transferrin receptor (sTfR) directly reflects the erythropoietic activity </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated sTfR concentrations in ineffective, dysplastic erythropoiesis in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: To exclude influences of other myeloid cells on sTfR, only patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) and 5q(-) syndrome were included </plain></SENT>
<SENT sid="3" pm="."><plain>sTfR was measured nephelometrically (<z:mpath ids='MPATH_458'>normal</z:mpath> range 0.81-1.75 mg/L) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Thirty-four untreated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (RA = 14, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> = 10, 5q(-) syndrome = 10) were enrolled and analysed </plain></SENT>
<SENT sid="5" pm="."><plain>The mean sTfR value of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (1.30 +/- 0.8 mg/L, range 0.2-3.8) did not differ from our control group </plain></SENT>
<SENT sid="6" pm="."><plain>In 5q(-) syndrome, the mean sTfR concentration (0.80 +/- 0.5 mg/L) was significantly lower than in RA (1.32 +/- 0.4 mg/L, P = 0.02) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> (1.75 +/- 1.1 mg/L, P = 0.03) </plain></SENT>
<SENT sid="7" pm="."><plain>Subdividing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> according to their amount of erythroid mass in bone marrow a significant difference of sTfR between patients with decreased (0.70 +/- 0.4 mg/L), <z:mpath ids='MPATH_458'>normal</z:mpath> (1.32 +/- 0.4 mg/L) and increased (2.06 +/- 0.9 mg/L) erythropoiesis was observed </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with sTfR values below the reference range of 0.81 mg/L required transfusions in 90% of cases and showed higher erythropoietin levels compared to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with sTfR levels &gt; or =0.81 mg/L (P = 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>There was a good agreement between sTfR and the amount of polychromatic erythroblasts observed (r = 0.68, P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: In conclusion, the serum concentration of sTfR reflects erythropoietic activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but it is in particular determined by the degree of erythroid maturation and the severity of <z:hpo ids='HP_0010972'>ineffective erythropoiesis</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Low sTfR values in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are associated with a reduced, poorly differentiated erythropoiesis and requirement of blood transfusions </plain></SENT>
</text></document>